Core Insights - The China International Import Expo (CIIE) has become a significant platform for global product launches and technological showcases, with Gilead Sciences emphasizing its role in accelerating innovative therapies for Chinese patients [2][3] Group 1: Company Participation and Strategy - Gilead Sciences is participating in the CIIE for the fourth time, highlighting China as a core strategic market and acknowledging the improved business environment [2] - The company aims to deepen collaborations across various sectors to advance healthcare in China, showcasing its commitment to health equity and drug accessibility [2][4] Group 2: Product Highlights - Gilead will showcase its long-acting HIV pre-exposure prophylaxis drug, Lenacapavir, which requires administration only twice a year, marking its global debut at the expo [2] - The company will also present 13 approved innovative drugs, including treatments for viral hepatitis and HIV, demonstrating advancements in patient care and disease management [3] Group 3: Collaborations and Impact - Gilead has established over 20 collaborations through the CIIE in the past three years, contributing to the enhancement of domestic treatment standards and the accessibility of innovative drugs [3] - The company signed a three-year strategic cooperation agreement with the China STD/AIDS Foundation to support hepatitis C case management, reflecting its commitment to addressing unmet medical needs in China [4]